RhumbLine Advisers’s Foundation Medicine, Inc. FMI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q3 | – | Sell |
-15,211
| Closed | -$2.08M | – | 2953 |
|
|
2018
Q2 | $2.08M | Buy |
15,211
+1,296
| +9% | +$118K | ﹤0.01% | 1652 |
|
|
2018
Q1 | $1.1M | Sell |
13,915
-244
| -2% | -$18K | ﹤0.01% | 1897 |
|
|
2017
Q4 | $966K | Sell |
14,159
-2,709
| -16% | -$140K | ﹤0.01% | 1961 |
|
|
2017
Q3 | $678K | Buy |
16,868
+240
| +1% | +$9.26K | ﹤0.01% | 2168 |
|
|
2017
Q2 | $661K | Buy |
16,628
+1,470
| +10% | +$53.8K | ﹤0.01% | 2165 |
|
|
2017
Q1 | $489K | Buy |
15,158
+668
| +5% | +$16.7K | ﹤0.01% | 2262 |
|
|
2016
Q4 | $256K | Buy |
14,490
+1,538
| +12% | +$33.1K | ﹤0.01% | 2563 |
|
|
2016
Q3 | $302K | Buy |
12,952
+125
| +1% | +$2.84K | ﹤0.01% | 2485 |
|
|
2016
Q2 | $239K | Buy |
12,827
+1,420
| +12% | +$25.7K | ﹤0.01% | 2650 |
|
|
2016
Q1 | $207K | Sell |
11,407
-55
| -0.5% | -$886 | ﹤0.01% | 2725 |
|
|
2015
Q4 | $241K | Buy |
11,462
+620
| +6% | +$11.9K | ﹤0.01% | 2697 |
|
|
2015
Q3 | $200K | Buy |
10,842
+234
| +2% | +$5.84K | ﹤0.01% | 2788 |
|
|
2015
Q2 | $359K | Sell |
10,608
-2,495
| -19% | -$100K | ﹤0.01% | 2537 |
|
|
2015
Q1 | $630K | Buy |
13,103
+2,405
| +22% | +$109K | ﹤0.01% | 2153 |
|
|
2014
Q4 | $238K | Sell |
10,698
-150
| -1% | -$3.46K | ﹤0.01% | 2702 |
|
|
2014
Q3 | $206K | Hold |
10,848
| – | – | ﹤0.01% | 2737 |
|
|
2014
Q2 | $292K | Buy |
+10,848
| New | +$275K | ﹤0.01% | 2614 |
|
RhumbLine Advisers's FMI Position: Q3 2018 in Review
RhumbLine Advisers sold out of Foundation Medicine, Inc. (FMI) in Q3 2018, closing a stake of 15,211 shares — an estimated $2.08M sold.
RhumbLine Advisers first reported a position in FMI in Q2 2014 and held it in 17 quarters. The position peaked at $2.08M in Q2 2018. 0 funds tracked by Wall St. Rank hold FMI as of Q3 2018.
- RhumbLine Advisers reported no remaining Foundation Medicine, Inc. position as of Q3 2018 after selling out during the quarter.
- RhumbLine Advisers sold 15,211 Foundation Medicine, Inc. shares in Q3 2018, an estimated $2.08M.
- RhumbLine Advisers first reported a position in Foundation Medicine, Inc. in Q2 2014 and held it in 17 quarters.
- RhumbLine Advisers's Foundation Medicine, Inc. position peaked at $2.08M in Q2 2018.
- 0 funds tracked by Wall St. Rank held Foundation Medicine, Inc. as of Q3 2018.
Based on RhumbLine Advisers's 13F filing for Q3 2018, filed 7 Nov 2018.